Profil
Dr. Lars Kåre Viksmoen, MD, is an Independent Director at PCI Biotech Holding ASA. He is on the Board of Directors at PCI Biotech Holding ASA and Labrida AS.
Dr. Viksmoen was previously employed as an Independent Director by Veloxis Pharmaceuticals A/S, a President & Chief Executive Officer by GN ReSound A/S, a Member-Executive Management by GN Store Nord A/S, a Chief Executive Officer by Biotec Pharmacon ASA, a Vice President & Regional Director-Europe by Merck & Co., Inc., and a Managing Director by MSD (Norge) AS.
He received his doctorate degree from the University of Oslo.
Postes actifs de Lars Kåre Viksmoen
| Sociétés | Poste | Début |
|---|---|---|
| PCI BIOTECH HOLDING ASA | Directeur/Membre du Conseil | 01/05/2016 |
Labrida AS
Labrida AS Medical SpecialtiesHealth Technology Develops and wholesales products for maintenance treatment of dental implants | Directeur/Membre du Conseil | - |
Anciens postes connus de Lars Kåre Viksmoen
| Sociétés | Poste | Fin |
|---|---|---|
GN Hearing A/S
GN Hearing A/S Medical SpecialtiesHealth Technology Manufactures hearing-aid devices | Directeur Général | 01/08/2014 |
| GN STORE NORD A/S | Corporate Officer/Principal | 01/08/2014 |
| ARCTICZYMES TECHNOLOGIES ASA | President | 01/03/2010 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/09/2006 |
MSD (Norge) AS
MSD (Norge) AS Pharmaceuticals: MajorHealth Technology Engages in researching, manufacturing and marketing of drugs | President | 01/01/1992 |
Formation de Lars Kåre Viksmoen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
PCI Biotech Holding ASA
PCI Biotech Holding ASA BiotechnologyHealth Technology Develops photochemical drug delivery technology for use in therapeutic treatment | Health Technology |
GN Store Nord A/S
GN Store Nord A/S Telecommunications EquipmentElectronic Technology Provides telecommunications and hearing instruments | Electronic Technology |
GN Hearing A/S
GN Hearing A/S Medical SpecialtiesHealth Technology Manufactures hearing-aid devices | Health Technology |
ArcticZymes Technologies ASA
ArcticZymes Technologies ASA Medical SpecialtiesHealth Technology Develops and manufactures immune modulating compounds | Health Technology |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MSD (Norge) AS
MSD (Norge) AS Pharmaceuticals: MajorHealth Technology Engages in researching, manufacturing and marketing of drugs | Health Technology |
Labrida AS
Labrida AS Medical SpecialtiesHealth Technology Develops and wholesales products for maintenance treatment of dental implants | Health Technology |
















